How did OBIO's revenue and expenses trend in Q4 2024?
4/14/2025 05:43am
Aime
Orchestra BioMed (OBIO) experienced a revenue of $633,000 in Q4 2024, with total expenses amounting to $16.87 million, comprising $10.97 million in R&D expenses and $5.9 million in selling, general, and administrative (SG&A) expenses1.
1/2
OBIO Revenue By Business
Source:
1.
OBIO Revenue by Business, R&D Expenses, Sales and Marketing Expenses, General and Administrative Expenses in Q4 2024
more
less
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized